Health Trials

An Open-label Study to Evaluate Safety, Tolerability, and Efficacy of CB03-154 in Subjects Diagnosed With Epilepsy

ConditionFocal Epilepsy
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-70
SponsorShanghai Zhimeng Biopharma, Inc.

About this trial

CB03-154 is an investigational drug developed by Shanghai Zhimeng Biopharma Inc. for the treatment of Focal Epilepsy.

Eligibility criteria

Qualifiers

1. The subject must be properly informed of the nature and risks of the study and give informed consent in writing, prior to entering the study.

Disqualifiers

None

Trial design

Treatments tested in this trial

  • CB03-154

Treatment groups

144 Participants
are divided into 1 treatment group

Sponsors and collaborators

Shanghai Zhimeng Biopharma, Inc.

Lead sponsor

Source ClinicalTrials.gov